Price Alert

Insulet Corporation (PODD)

NASDAQ: PODD · Real-Time Price · USD

331.83

2.83 (0.86%)

At close: Aug 26, 2025, 3:59 PM

333.33

0.45%

Pre-market: Aug 27, 2025, 09:11 AM EDT

0.86% (1D)

Bid	327.05
Market Cap	23.36B
Revenue (ttm)	2.36B
Net Income (ttm)	236.1M
EPS (ttm)	3.29
PE Ratio (ttm)	100.86
Forward PE	56.53
Analyst	Buy

Ask	333
Volume	458,428
Avg. Volume (20D)	717,031
Open	330.58
Previous Close	329.00
Day's Range	328.87 - 332.33
52-Week Range	183.31 - 334.18
Beta	1.35

About PODD

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PODD

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PODD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Insulet Corporation is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+9.47%

Insulet shares are trading higher after the compan... Unlock content with Pro Subscription

1 month ago

-4.52%

Shares of glucose monitor and insulin pump stocks are trading lower after the CMS proposed that continuous glucose monitors and insulin infusion pumps be reclassified under the frequent and substantial servicing payment category.

News

1 day ago · businesswire.com

Insulet Elevates Eric Benjamin to Chief Operating Officer

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...

1 day ago · zacks.com

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

4 days ago · zacks.com

Insulet Gains 77.2% in a Year: What's Driving the Rally?

PODD's 77.2% stock surge is fueled by Omnipod 5 expansion, global launches, strong Q2 profits and robust financial stability.

6 days ago · investors.com

Omnipod Maker Hit A Buy Point. Here's Where To Pick Up Shares.

The Omnipod maker reported 113% earnings growth, sending shares higher.

1 week ago · youtube.com

Final Trades: Rocket Companies, Cisco Systems, Insulet Corp and the IGV

The Investment Committee give you their top stocks to watch for the second half.

1 week ago · businesswire.com

Insulet to Participate in Upcoming Investor Conferences

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will prese...

1 week ago · seekingalpha.com

Insulet's Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold

PODD delivered strong Q2 results, exceeding revenue guidance, improving gross margin, and launching the Omnipod 5 iPhone app, strengthening its ecosystem position. Omnipod 5's pharmacy channel penetra...